Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | S100A4 | P26447 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144190 | 0.83 | ALDH1A1 (0.62) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| Bromide SCHEMBL8457695 | 0.82 | ALDH1A1 (0.60) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| SCHEMBL27544019 | 0.81 | HSPB1 (0.53) | ALDH1A1MAPK1MEN1KMT2AKDM4E | |
| SCHEMBL30317899 | 0.80 | PTPRC (0.54) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| SCHEMBL3277269 | 0.80 | PTPRC (0.54) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| 4-Nitrocatechol SCHEMBL156909 | 0.80 | TSHR (0.69) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| SCHEMBL11028069 | 0.80 | GPR35 (0.69) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| 4-Nitrocatechol SCHEMBL11765698 | 0.80 | TSHR (0.69) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| 4-Nitrocatechol SCHEMBL1608536 | 0.80 | TSHR (0.69) | GPR35ALDH1A1TSHRHPGDMAPK1 | |
| SCHEMBL7741732 | 0.78 | PTPRC (0.63) | GPR35ALDH1A1TSHRHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604929-B2 | Functionalized carbon nanoparticles and functional polymer fibers prepared using the same | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-03-28 | — | — | US | claimed |
| US-20150204009-A1 | FUNCTIONALIZED CARBON NANOPARTICLES AND FUNCTIONAL POLYMER FIBERS PREPARED USING THE SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-07-23 | — | — | US | claimed |
| EP-4748837-A1 | AROMATIC AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| CN-122070287-A | IRAK 4-targeted degradation agent compound and application thereof | 江苏先声药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | LEUKOS BIOTECH, S.L. (ES) | 2026-02-03 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001062704-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
| US-4417896-A | NITRO-,AMINO-,PHENOXYALKANOLS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-11-29 | — | — | US | disclosed |
| US-4337061-A | NITRO DYES IN AQUEOUS SOLUTION | SOCIETE ANONYME DITE: L'OREAL (FR) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | GPR35 191/4885ALDH1A1 1180/4885TSHR 141/4885 |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | HTR3B, HTR1A, HTR1B | GPR35 187/4885ALDH1A1 1283/4885TSHR 135/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | GPR35 4040/4885ALDH1A1 4265/4885TSHR 1614/4885 |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1A | GPR35 2409/4885ALDH1A1 2383/4885TSHR 2019/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | GPR35 2654/4885ALDH1A1 3016/4885TSHR 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.